Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

Rhea-AI Summary

Oculis (Nasdaq: OCS) reported its Q4 and full year 2024 financial results, highlighting significant clinical advancements across its pipeline. The company completed an oversubscribed $100 million equity financing and reported cash position of $109 million as of December 31, 2024, providing runway into early 2028.

Key clinical developments include positive topline results from the ACUITY Phase 2 trial of Privosegtor (OCS-05) in acute optic neuritis and the RELIEF trial of Licaminlimab (OCS-02) in dry eye disease. The company is on track to complete enrollment for Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema.

Financial highlights:

• Q4 2024 net loss: $32.6 million vs $14.1 million in Q4 2023
• FY2024 net loss: $97.4 million vs $98.8 million in 2023
• R&D expenses increased to $59.1 million in 2024 from $32.6 million in 2023
• G&A expenses rose to $24.8 million in 2024 from $19.5 million in 2023

Positive

• Successful $100 million equity financing completed
• Positive Phase 2 trial results for both Privosegtor and Licaminlimab
• Strong cash position of $202 million providing runway into early 2028
• On track for Phase 3 DIAMOND trials enrollment completion

Negative

• Increased net loss in Q4 2024 to $32.6M from $14.1M in Q4 2023
• R&D expenses nearly doubled to $59.1M in 2024
• G&A expenses increased by 27% to $24.8M in 2024

Insights

Financial Analyst

Oculis' Q4 and FY2024 results demonstrate solid strategic execution amid increasing R&D investments. The company reported $109 million in cash and investments as of December 31, 2024, bolstered by an oversubscribed $100 million equity financing that extends runway into early 2028 - providing approximately 3 years of operational funding at current burn rates.

Q4 net loss widened to CHF 28.7 million ($32.6 million) from CHF 12.5 million in Q4 2023, driven by increased R&D expenses (CHF 11.8 million, up 47.5% YoY) and non-cash warrant valuation changes. Full-year non-IFRS loss grew to CHF 85.8 million ($97.4 million) from CHF 49.0 million in 2023.

The higher expenditures reflect accelerated clinical development across three late-stage programs: OCS-01 for diabetic macular edema (Phase 3), Privosegtor for acute optic neuritis (positive Phase 2), and Licaminlimab for dry eye disease (positive Phase 2b). This investment profile is typical for biotech companies advancing multiple clinical-stage assets simultaneously.

The recent financing significantly strengthens Oculis' balance sheet, reducing near-term funding risk and providing operational flexibility to pursue potential commercialization of its most advanced candidates. With key clinical catalysts ahead and multiple shots on goal in ophthalmology indications with substantial market opportunities, the strong cash position positions Oculis well for continued pipeline advancement through critical development milestones.

Pharmaceutical Researcher

Oculis has achieved significant clinical milestones across its differentiated ophthalmology portfolio. Most notable is Privosegtor (OCS-05)'s positive Phase 2 ACUITY trial results in acute optic neuritis, where the drug demonstrated neuroprotective benefits in retinal preservation and visual function - addressing a serious condition with treatment options. The results achieved three secondary efficacy endpoints showing improvements in objective structural and functional measures versus placebo.

The company's pipeline diversity spans three critical areas: retinal diseases (OCS-01 for DME), neuro-ophthalmology (Privosegtor for optic neuritis), and precision medicine (Licaminlimab for dry eye). This balanced approach targets conditions with substantial unmet needs while diversifying clinical development risk.

Enrollment for the twin Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema is progressing toward completion, with topline results expected in H1 2026. This represents Oculis' most advanced program, with NDA submission for post-ocular surgery indication also on track for Q1 2025.

The Licaminlimab (OCS-02) program employs a precision medicine approach in dry eye disease, with positive Phase 2b RELIEF trial results and FDA confirmation of the development pathway. This targeted strategy could potentially differentiate the product in the competitive dry eye market by identifying specific patient populations most likely to benefit.

With FDA interactions planned for Privosegtor in H2 2025 and upcoming pipeline updates at their April R&D Day, Oculis has positioned itself as an emerging leader in addressing both front and back-of-eye conditions with novel therapeutic approaches.

• Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic (Privosegtor, OCS-05, in acute optic neuritis) and precision medicine (Licaminlimab, OCS-02, in dry eye disease) treatments
• Recent positive topline results in the ACUITY Phase 2 trial showed Privosegtor (OCS-05)’s neuroprotective benefits in anatomical preservation of the retina and visual function improvements in acute optic neuritis
• Oversubscribed $100 million equity financing completed to support the advancement of Oculis’ late-stage clinical portfolio
• Upcoming R&D Day planned on April 15, 2025, to showcase pipeline potential and company strategy
• Cash, cash equivalents and short-term investments of $109 million as of December 31, 2024, together with approximately $93 million net proceeds of recent financing provides cash runway into early 2028
  

ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the quarter and full year ended December 31, 2024, and provided an overview of the Company’s progress.

Riad Sherif M.D., Chief Executive Officer of Oculis: “We had a momentous year in 2024, and a strong start to 2025. We delivered two positive Phase 2 topline readouts from the ACUITY Privosegtor (OCS-05) trial in acute optic neuritis showing neuroprotective effects and the RELIEF trial of Licaminlimab (OCS-02) in dry eye disease (DED) with a precision medicine approach. In addition, we are on track to complete enrollment in the coming months for both Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema (DME). The recent $100 million equity financing is another significant milestone for Oculis to propel its pipeline. As we continue to execute on our vision to be a leader in ophthalmic and neuro-ophthalmic fields and to bring innovative sight-saving treatments to market, 2025 will be a year in which we remain focused on execution to advance our late-stage clinical portfolio. We look forward to sharing updates on our portfolio strategy at our upcoming R&D Day.”

Q4 2024 and Recent Highlights

Clinical Highlights and Upcoming Milestones:

• OCS-01:
  • On-track to complete enrollment in Phase 3 DIAMOND program in DME with top-line data readout expected in first half of 2026.
  • NDA submission readiness for post-ocular surgery also on track in Q1 2025.
    
    
• Privosegtor (OCS-05):
  
  
  • Positive topline results from the Phase 2 ACUITY trial in patients with acute optic neuritis where Privosegtor (OCS-05) achieved primary endpoint of safety and three secondary efficacy endpoints demonstrating improvement for Privosegtor (OCS-05) compared to placebo in objective structural measures of retinal thickness and functional vision improvement.
  • FDA interactions are planned for the second half of 2025 to discuss the ACUITY trial results and align on the next steps, including a registrational development program for acute optic neuritis.
    
    
• Licaminlimab (OCS-02):
  
  
  • Positive readout from the Phase 2b RELIEF trial in signs of DED and FDA interaction conducted in Q1 2025 confirmed development path forward with a precision medicine approach.

Further business and pipeline development updates to be provided during the R&D Day on April 15, 2025 in New York City.

Q4 and Full Year 2024 Financial Highlights

• Cash position: As of December 31, 2024, the Company had total cash, cash equivalents and short-term investments of CHF 98.7 million or $109.0 million, compared to CHF 91.7 million or $108.9 million as of December 31, 2023. The increase in cash position from December 31, 2023 reflects the proceeds from the registered direct offering in the second quarter of 2024. Based on its cash, cash equivalents and short-term investments at December 31, 2024 and approximately $93 million in net proceeds received from the recent financing, and its development plans, the Company’s cash balances are expected to fund operations into early 2028.
• Research and development expenses were CHF 11.8 million or $13.4 million for the three-months ended December 31, 2024, compared to CHF 8.0 million or $9.0 million in the same period in 2023. Research and development expenses for the year ended December 31, 2024 were CHF 52.1 million or $59.1 million, compared to CHF 29.2 million or $32.6 million in the previous year. The increase was primarily due to clinical development expenses for the active clinical trials for OCS-01 in DME, Privosegtor (OCS-05) in acute optic neuritis and Licaminlimab (OCS-02) in DED.
• General and administrative expenses were CHF 5.5 million or $6.3 million for the three-months ended December 31, 2024, compared to CHF 4.3 million or $4.9 million in the same period in 2023. General and administrative expenses for the year ended December 31, 2024 were CHF 21.8 million or $24.8 million, compared to CHF 17.5 million or $19.5 million in the previous year. The increase was primarily due to share-based compensation expenses.
• Q4 net loss was CHF 28.7 million or $32.6 million for the fourth quarter ended December 31, 2024, compared to CHF 12.5 million or $14.1 million for the same period in 2023. The increase was primarily driven by changes in the fair value (non-cash) of outstanding warrants, increased clinical development costs and increased share-based compensation expenses.
• FY2024 net loss was CHF 85.8 million or $97.4 million for the year ended December 31, 2024, compared to CHF 88.8 million or $98.8 million for the same period in 2023. The decrease was primarily due to a non-recurring and non-cash merger and listing expense recorded in 2023 of CHF 34.9 million or $38.2 million, partially offset by changes in the fair value of outstanding warrants, increases in clinical development costs and expenses incurred to operate as a dual-listed public company.
• FY2024 non-IFRS net loss was CHF 85.8 million or $97.4 million, or CHF 2.12 or $2.41 per share, for the year ended December 31, 2024, compared to CHF 49.0 million or $54.5 million, or CHF 1.64 or $1.83 per share, for the same period in 2023. The increase in non-IFRS net loss was primarily driven by changes in the fair value of outstanding warrants and the advancement of clinical development programs during the year, including the Phase 3 DIAMOND-1 and DIAMOND-2 trials for DME, Phase 2 ACUITY trial for acute optic neuritis, and Phase 2 RELIEF trial for DED.

Non-IFRS Financial Information

This press release contains financial measures that do not comply with International Financial Reporting Standards (IFRS) including non-IFRS loss, and non-IFRS loss attributable to equity holders per common share. These non-IFRS financial measures exclude the impact of items that the Company’s management believes affect comparability or underlying business trends. These measures supplement the Company’s financial results prepared in accordance with IFRS. The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook. In management’s opinion, these non-IFRS measures are useful to investors and other users of the Company's financial statements by providing greater transparency into the ongoing operating performance of the Company and its future outlook. Such measures should not be deemed to be an alternative to IFRS requirements.

The non-IFRS measures for the reported periods reflect adjustments made to exclude:

• Merger and listing expense, which was a one-time and non-cash expense of CHF 34.9 million or $38.2 million in the year-to-date 2023 total operating expenses.
  
  
• During the third quarter of 2023, the Company gave effect to the dissolution of its Merger Sub 2 entity pursuant to the Business Combination Agreement with EBAC. As a result, the cumulative translation adjustments related to Merger Sub 2 previously reported in equity and recognized in other comprehensive loss, were reclassified from equity to the Condensed Consolidated Interim Statement of Loss for the year ended December 31, 2023. The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the year ended December 31, 2023.

	Consolidated Statements of Financial Position
	(Amounts in CHF thousands)	As of December 31,		As of December 31,
		2024		2023
	ASSETS
	Non-current assets
	Property and equipment, net	385		288
	Intangible assets	13,292		12,206
	Right-of-use assets	1,303		755
	Other non-current assets	476		89
	Total non-current assets	15,456		13,338
	Current assets
	Other current assets	5,605		8,488
	Accrued income	629		876
	Short-term financial assets	70,955		53,324
	Cash and cash equivalents	27,708		38,327
	Total current assets	104,897		101,015
	TOTAL ASSETS	120,353		114,353
	EQUITY AND LIABILITIES
	Shareholders' equity
	Share capital	446		366
	Share premium	344,946		288,162
	Reserve for share-based payment	16,062		6,379
	Actuarial loss on post-employment benefit obligations	(2,233)		(1,072)
	Treasury shares	(10)		-
	Cumulative translation adjustments	(271)		(327)
	Accumulated losses	(285,557)		(199,780)
	Total equity	73,383		93,728
	Non-current liabilities
	Long-term lease liabilities	865		431
	Long-term payables	-		378
	Defined benefit pension liabilities	1,870		728
	Total non-current liabilities	2,735		1,537
	Current liabilities
	Trade payables	5,871		7,596
	Accrued expenses and other payables	18,198		5,948
	Short-term lease liabilities	315		174
	Warrant liabilities	19,851		5,370
	Total current liabilities	44,235		19,088
	Total liabilities	46,970		20,625
	TOTAL EQUITY AND LIABILITIES	120,353		114,353

Consolidated Statements of Loss
(Amounts in CHF thousands, except per share data)		For the three months ended December 31,				For the years ended December 31,
		2024		2023		2024		2023
Grant income		3		185		686		883
Operating income		3		185		686		883
Research and development expenses		(11,763)		(8,029)		(52,083)		(29,247)
General and administrative expenses		(5,500)		(4,340)		(21,807)		(17,487)
Merger and listing expense		-		-		-		(34,863)
Operating expenses		(17,263)		(12,369)		(73,890)		(81,597)
Operating loss		(17,260)		(12,184)		(73,204)		(80,714)
Finance income		371		656		2,168		1,429
Finance expense		(247)		(12)		(639)		(1,315)
Fair value adjustment on warrant liabilities		(13,387)		1,207		(15,531)		(3,431)
Foreign currency exchange loss, net		1,630		(2,179)		1,269		(4,664)
Finance result, net		(11,633)		(328)		(12,733)		(7,981)
Loss before tax for the period		(28,893)		(12,512)		(85,937)		(88,695)
Income tax expense		238		13		160		(107)
Loss for the period		(28,655)		(12,499)		(85,777)		(88,802)
Loss per share:
Basic and diluted loss attributable to equity holders		(0.67)		(0.34)		(2.12)		(2.97)

Reconciliation of Non-IFRS Measures (Unaudited)
(Amounts in CHF thousands, except per share data)
	For the years ended December 31,
	2024		2023
IFRS loss for the period	(85,777)		(88,802)
Non-IFRS adjustments:
Merger and listing expense (i)	-		34,863
Merger Sub 2 reclassification from equity to foreign exchange loss (ii)	-		4,978
Non-IFRS loss for the period	(85,777)		(48,961)
IFRS basic and diluted loss attributable to equity holders	(2.12)		(2.97)
Non-IFRS basic and diluted loss attributable to equity holders	(2.12)		(1.64)
IFRS weighted-average number of shares used to compute loss per share basic and diluted	40,406,551		29,899,651
(i) Merger and listing expense is the difference between the fair value of the shares transferred and the fair value of the EBAC net assets per the Business Combination Agreement. This merger and listing expense is non-recurring in nature and represented a share-based payment made in exchange for a listing service and does not lead to any cash outflows.
(ii) The reclassification of cumulative translation adjustments from equity to foreign exchange loss results from the impact of the dissolution of Merger Sub 2. This exchange loss is non-recurring in nature and does not lead to any cash outflows.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS / XICE: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline of multiple innovative product candidates in clinical development includes: OCS-01, a topical eye drop candidate for diabetic macular edema (DME); Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor & Media Relations

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, the timing, progress and results of current and future clinical trials, including the Company’s Phase 3 DIAMOND program in DME, Oculis’ research and development programs, regulatory and business strategy, future development plans; the timing or likelihood of regulatory filings and approvals; and the Company’s expected cash runway are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and other documents filed with the U.S. Securities and Exchange Commission (the “SEC”). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

FAQ

What were the key clinical trial results for Oculis (OCS) in 2024?

Oculis reported positive topline results from ACUITY Phase 2 trial for Privosegtor in acute optic neuritis and RELIEF trial for Licaminlimab in dry eye disease.

How much cash does Oculis (OCS) have and what is their runway?

Oculis has $109 million in cash as of December 31, 2024, plus $93 million from recent financing, providing runway into early 2028.

When will Oculis (OCS) report Phase 3 DIAMOND trial results for DME?

Oculis expects top-line data readout from Phase 3 DIAMOND trials in diabetic macular edema in first half of 2026.

How did Oculis (OCS) R&D expenses change in 2024 compared to 2023?

R&D expenses increased to $59.1 million in 2024 from $32.6 million in 2023 due to active clinical trials.

What is the next major corporate event for Oculis (OCS)?

Oculis will hold an R&D Day on April 15, 2025, in New York City to showcase pipeline potential and company strategy.